Posted by AGORACOM
at 8:33 AM on Monday, April 29th, 2019
OTTAWA, April 29, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altusâ€)
today announced the signing of a Joint Venture Agreement under which
the two companies will work together to develop a series of
cannabinoid-receptor targeted therapeutics addressing multiple areas of
high unmet need.
The Joint-Venture will synergize the capabilities of the two companies:
Products: The companies have identified product candidates in the
fields of pain, oncology and ophthalmology, addressing a total market
size of over $10BN. (Source: MedTrack™)
New Routes of Administration: Altus’ SmartCelle™ insoluble drug
delivery platform enables intravenous, topical, intra-nasal and oral
delivery. Smartcelle’s™ proven ability to enhance the solubility of
cannabinoids permits increased oral absorption and enables low volume
parenteral and transmucosal delivery. Intellitab™ and Flexitab™
technologies will deliver Safer to Use™ products to patients.
New Intellectual Property: Altus’ distinct drug delivery
technologies provide Tetra with significant strategic advantages over
the competition and will enable Tetra to significantly improve some of
the current products under development. In addition to SmartCelle™ these
include Intellitab™ abuse deterrent technology platform and, Flexitab™
breakable sustained release tablet technology for enhanced dosing
flexibility. All platforms are protected by patents enforced globally.
Commercial Development, Manufacturing and Supply. Combining Altus
and Tetra capabilities ensures these essential parts of the value chain
are addressed early and efficiently.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are extremely
excited about finalizing this agreement which will enable us to improve
existing products and will allow us to exploit a number of different
delivery mechanisms including Intra-Nasal, Intravenous and Oral
Sustained Release Tablets. Furthermore, Altus’ technology will play a
key role in strengthening Tetra’s Intellectual Property for its product
portfolio. This newly created joint-venture will also serve to benefit
our patients, their care providers and help us in our quest to replace
the use of opioids.â€
Damon Smith President and CEO of Altus Formulations Inc. added, “We
believe that by targeting cannabinoid receptors we open up a range of
therapeutic pathways unaddressed by today’s medications. Whether alone
or in combination, we believe such medications can provide great value
to patients, not least to those suffering the blight of undertreated
pain. By combining our capabilities and focusing our resources to
generate the right drug for the right patient, the Tetra/Altus joint
venture overcomes many of the hurdles that have dogged cannabinoid
medicine commercialization in the past. We greatly look forward to
working with the Tetra team and to bringing these products to the
market.
About Altus Formulation Inc. Altus Formulation is
a Quebec based drug formulation and development company using its
proprietary and patent protected drug delivery technologies to generate
novel, differentiated and cost-effective new products for its partners
and their patients. With a focus on Safer to Use™ formulations, Altus’
technologies include Intellitab™ abuse deterrent technology, Flexitab™
breakable extended release tablets and SmartCelle™ technologies for
delivery of low solubility large and small molecules.
About Tetra Bio-Pharma Inc. Tetra Bio-Pharma
(TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health Canada
approved, and FDA reviewed, clinical program aimed at bringing novel
prescription drugs and treatments to patients and their healthcare
providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals,
Natural Health and Veterinary Health Products containing cannabis and
other medicinal plant-based elements. With patients at the core of what
we do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing bio
pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:18 PM on Wednesday, January 30th, 2019
The Proposed Transaction is expected to:
provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabinoid company;
provide Tetra with more pharmaceutical and natural health products;
allow Tetra to sell these products worldwide;
give Tetra access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
ORLEANS, ON, Jan. 30, 2019 - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSXV: TBP) (OTCQB: TBPMF), today announced it has entered into a definitive agreement (the “Agreement“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“).  Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.  Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of
Tetra stated, “In completing this acquisition of Panag Pharma we have
not only acquired a large portfolio of cannabinoid derived
pharmaceutical and natural health products but also a team of scientists
that have a substantial amount of expertise in the field. Tetra
Bio-Pharma looks forward to incorporating Panag into its operations and
accelerating its various drug development programs including our
second-generation inhaled program.”
Following the closing of the Proposed Transaction, it is expected
that Panag will remain a separate subsidiary owned 100% by Tetra and
provide Tetra with additional discovery and early phase drug development
capacity. With this robust product pipeline, Tetra intends to continue
to implement its out-licensing program to generate additional revenues
via upfront payments, milestone payments, and royalties and actively
pursue the clinical development of lead products.
According to Dr. Orlando Hung, a
co-founder of Panag, “The Panag team is very excited to have this
well-timed opportunity with Tetra Bio-Pharma, allowing us to continue
our decades of translational cannabinoid research. Utilizing the
expertise and support from Tetra Bio-Pharma, we are confident that our
partnership and combined skills will position us to bring effective and
safe cannabinoid-based medications, as well as more innovative
cannabinoid delivery systems to market to help managing patients with
pain and inflammation.”
Pursuant to the Agreement, Tetra would acquire 100% of the issued and
outstanding shares of Panag for an aggregate consideration of $12,000,000,
on a debt-free basis and subject to customary post-closing adjustments.
The purchase price would be payable by Tetra delivering to the Vendors,
on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra (“Common Shares“),
at a price per Common Share equal to the lesser of (i) the 10-day
volume weighted average price of the Common Shares ending as of the date
of the Agreement and (ii) the Discounted Market Price (as that term is
defined in the policies of the TSX Venture Exchange (“TSXV“)) of
the Common Shares as at the date that is three business days prior to
the closing date of the Proposed Acquisition. The Agreement also
contemplates the payment by Tetra to the Vendors of an aggregate amount
of up to $15,000,000 in cash in milestone
payments upon the achievement of operational targets associated with
marketing approvals and commercialization of both human and veterinary
drug products by the U.S. Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). Tetra is committed to fund Panag’s
research in an amount no less than $1,200,000
annually for a period of ten years after the closing date of the
Proposed Acquisition. The milestone payments would be accelerated in the
event of a bankruptcy, insolvency, failure of Tetra to make its funding
commitments to Panag, change of control or sale of all of the assets of
Tetra at any time until December 31, 2028.
In addition, in the event of a change of control of Tetra within 24
months of the closing date of the Proposed Acquisition, the Vendors
would be entitled to receive from Tetra an additional $10 million.
Two of the Vendors, Bill Cheliak and Gregory Drohan,
are non-arm’s length parties to Tetra within the meaning of the rules
of the TSXV. Mr. Cheliak is the Chairman of the board of directors of
the Company (the “Board“) and Mr. Drohan is a director of the
Company. The Proposed Transaction will not result in the issuance of
securities to non-arm’s length parties as a group as payment of the
purchase price exceeding 10% of the number of outstanding shares of the
Company on a non-diluted basis.
The Board formed a special committee (the “Special Committee“) for purposes of evaluating the Proposed Transaction. The Special Committee was composed of Benoit Chotard and Carl Merton, both of whom have no interest in Panag or the Proposed Transaction. On December 24, 2018, the Special Committee received a fairness opinion (the “Fairness Opinion“)
from Paradigm Capital stating that the purchase price under the
Proposed Transaction is fair, from a financial point of view, to the
shareholders of Tetra. In light of the Fairness Opinion and of other
considerations and upon the recommendation of the Special Committee, the
Board approved the Proposed Transaction. Because of their interests in
the Proposed Transaction, Mr. Cheliak and Mr. Drohan recused themselves
from all meetings and discussions of the Board relating to the Proposed
Transaction and abstained from voting on the resolutions of the Board
approving the Proposed Transaction.
The Company expects that the Proposed Transaction will be completed in February 2019.
Completion of the Proposed Transaction remains subject to a number of
conditions, including the receipt of the approval of the TSXV and such
other closing conditions as are customary in transactions of this
nature. There can be no assurance that such conditions will be
satisfied and that the Proposed Transaction will be completed as
described or at all.
Neither the TSXV nor its Regulation Services Provider (as that term
is defined in the policies of the TSXV) accepts responsibility for the
adequacy or accuracy of this release.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Panag Pharma Inc. is a Canadian based bio-tech company focused on the
development of novel cannabinoid-based formulations for the treatment
of pain and inflammation. Panag believes that pain relief should be
safe, non-addictive and above all; effective. The Panag Pharma team of
PhD scientists and medical doctors are among the world’s
leading researchers and clinicians in pain treatment and management.
They bring a combined experience of over 100 years in research and
clinical care of people dealing with chronic pain and inflammatory
conditions. Panag’s current pipeline of pain relief products include
formulations for the topical application to the skin, the eye and other
mucous membranes. Recently approved by Health Canada and currently
undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new
approach to the treatment of chronic pain and inflammation.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that address
activities, events or developments that the Companybelieves,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding: the anticipated benefits of
the Proposed Transaction for Tetra; completion and expected timing of
the Proposed Transaction; whether the terms of the Proposed Transaction
will be as described in this press release; whether the Proposed
Transaction will be successful; the receipt of the approval of the TSXV in
respect of the Proposed Transaction) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words “may”, “will”, “should”, “continue”, “expect”, “anticipate”,
“estimate”, “believe”, “intend”, “plan” or “project” or the negative of
these words or other variations on these words or comparable
terminology. Forward-looking statements are subject to a number of risks
and uncertainties, many of which are beyond the Company’s ability to
control or predict, that may cause the actual results of the Company to
differ materially from those discussed in the forward-looking
statements. Factors that could cause actual results or events to differ
materially from current expectations include, among other things,
without limitation, the inability of the Company to obtain sufficient
financing to execute the Company’s business plan; competition;
regulation and anticipated and unanticipated costs and delays, the
success of the Company’s research and development strategies, including
the completion of the Proposed Transaction, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical trials,
the timing and outcomes of regulatory or intellectual property
decisions and other risks disclosed in the Company’s public disclosure
record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that
could cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors that
cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on forward-looking
statements. No definitive documentation has yet been signed by the
parties and there is no certainty that such documentation will be
signed. The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or otherwise
unless required by applicable securities legislation.
please contact Tetra Bio-Pharma Inc.: Guy Chamberland, Ph.D., Chief
Executive Officer and Chief Scientific Officer, 514-220-9225,
[email protected]; Media Contact: Energi PR, Carol Levine,
514-288-8500 ext. 226, [email protected]; Stephanie Engel,
416-425-9143 ext. 209, [email protected] CNW Group
2019
Tags: Cannabinoid, tsx Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Posted by AGORACOM
at 9:12 AM on Monday, October 22nd, 2018
Expanded its product line and launched a hemp-derived CBD product pet line under the HerbalPet brand.
The products will be sold on herbalpet new website (www.herbalpet.com) and in select locations in the U.S
The CBD chews contain several important ingredients that promote good health.
LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) — Applied Biosciences Corp. (OTCQB: APPB) a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has expanded its product line and launched a hemp-derived CBD product pet line under the HerbalPet brand. The products will be sold on herbalpet new website (www.herbalpet.com) and in select locations in the U.S
Although the health benefits of CBD are becoming well known, one of the challenges of working with CBD is its bitter after taste. We commonly hear this feedback in humans and the bitterness is also true for pets. Aromas from CBD are strong and to a dog that level of concentration can be displeasing. To overcome this issue, we specifically formulated the product line with natural, high protein, human grade chicken meat – our number 1 ingredient – that dog’s love.
In addition to CBD, these chews contain several important ingredients that promote good health. In the calming support chew, consists of super foods (sweet potato and turmeric) as well as antioxidants (organic chamomile) and a natural amino acid (L-Theanine). The mobility support chew also has bone broth, glucosamine, chondroitin for bone health. It is also grain-free. Importantly, these products contain no synthetic preservatives, no fillers, no Genetically Engineered Ingredients (GMO) and no animal feed ingredients.
“Remedi continues to be at the forefront of the cannabinoid market, first using organically grown plants, without pesticides or herbicides as our main ingredient and now quickly and easily providing consumers with a variety of tinctures, topical creams and alternatives to the growing demand of this space. As Applied BioSciences continues to launch our product lines in select specialty and retail stores, people will also be able to visit remedishop.com to find a holistic health and wellness alternatives that best suit their lifestyle.†commented Chris Bridges, President of Applied BioSciences Corp.
Applied BioSciences products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.
About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has expanded and launched a hemp derived CBD pet line under the Herbal Pet brand. The products will be sold on Herbal Pet’s new website (http://www.herbalpet.com) and in select locations in the U.S.
Although the health benefits of CBD are now considered well known, one of the challenges of working with CBD is its bitter after taste. Applied Biosciences focused on this common feedback from humans and developed formulations to improve the experience for both humans and pets. Aromas from CBD are strong and to a dog, that level of concentration can be displeasing. To overcome this issue, the product line (including our chews) has been specifically formulated with natural, high protein, human grade chicken meat – our number 1 ingredient.
In addition to CBD, these chews contain several important ingredients that promote good health. The calming support chew consists of super foods (sweet potato and turmeric) as well as antioxidants (organic chamomile) and a natural amino acid (L-Theanine). The mobility support chew also has bone broth, glucosamine, and chondroitin for bone health. It is also grain-free. Importantly, these products contain no synthetic preservatives, no fillers, no Genetically Engineered ingredients (GMO) and no animal feed ingredients.
“Applied BioSciences continues to be at the forefront of the cannabinoid market, first using organically grown plants, without pesticides or herbicides as our main ingredient and now quickly and easily providing consumers with a variety of tinctures, topical creams and alternatives to the growing demand of this space. Our company continues to launch our product lines in select specialty and retail stores, people and pet owners will also be able to visit our websites to find holistic health and wellness alternatives that best suit their lifestyle,†commented Chris Bridges, President of Applied BioSciences Corp.
Applied BioSciences products are USDA-NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC- free. Our products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.
About Applied BioSciences Corp.
Applied BioSciences Corp. (http://www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Contact
Email: ir(at)appliedbiocorp.com or info(at)appliedbiocorp.com
To be added to the Applied BioSciences email distribution list, please email info(at)appliedbiocorp.com with APPB in the subject line.
Posted by AGORACOM-JC
at 8:43 AM on Friday, September 21st, 2018
WHY NORTH BUD FARMS INC?
Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
Infused products sector has become the highest margin segment of the industry
Positioned to be a raw input producer for this space
Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
THE OPPORTUNITY
Acquired late stage ACMPR applicant GrowPros
MMP from Tetra Bio-Pharma (TSXV: TBP)
GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs
LOCATION
SITE DETAILS: LOW COST INFRASTRUCTURE
POSITIONED FOR LEGALIZATION 2.0
First mover advantage often becomes first-mover disadvantage
Examples: AOL, Netscape, Yahoo, BlackBerry
Second mover advantage: clearer picture of market and competition
Examples: Google, Facebook, Amazon, Apple, NORTHBUD
STRATEGIC VERTICALS
Pharma Development
North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.
Food Grade Inputs
Using our licensed encapsulation technology we will
engage existing food and beverage companies looking
to develop product lines containing cannabis.
